Examining Recent Developments in Frontline HCC Treatment

home / publications / supplements / examining-recent-developments-in-frontline-hcc-treatment
Amit Singal, MD

Dr. Singal on the FDA Approval of Durvalumab With Tremelimumab in Unresectable HCC

Amit Singal, MD, MS
December 13th 2022
Video

Amit Singal, MD, discusses the FDA approval of durvalumab with tremelimumab (Imjudo) in unresectable hepatocellular carcinoma.

Richard Kim, MD

Dr. Kim on The Evaluation of TKI/Immunotherapy Combos in HCC

Richard Kim, MD
November 11th 2022
Video

Richard Kim, MD, discusses the evaluation of TKI and immunotherapy combination regimens in hepatocellular carcinoma.

Rachna T. Shroff, MD, MS

Dr. Shroff on the Utility of the HIMALAYA Regimen in HCC

Rachna T. Shroff, MD, University of Arizona Cancer Center
November 7th 2022
Video

Rachna T. Shroff, MD, MS, discusses the utility of combining anti–CTLA-4 and anti–PD-1 therapies in hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD

Dr. Abou-Alfa on Areas Ripe for Further Exploration in HCC

Ghassan Abou-Alfa, MD
November 3rd 2022
Video

Ghassan K. Abou-Alfa, MD, discusses areas ripe for further exploration in hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD

Dr. Abou-Alfa on Analyzing Disease Factors to Inform Clinical Decisions in HCC

Ghassan K. Abou-Alfa, MD
October 18th 2022
Video

Ghassan K. Abou-Alfa, MD, discusses the analysis of disease and patient factors to inform clinical decisions in hepatocellular carcinoma.

Laura Goff, MD

Dr. Goff on Leveraging Clinical Trial Information to Inform Treatment Decisions in HCC

Laura W. Goff, MD
October 18th 2022
Video

Laura Goff, MD, discusses how to consider clinical trial information to inform treatment decisions in patients with hepatocellular carcinoma.

Rachna T. Shroff, MD, MS

Dr. Shroff on Remaining Unmet Needs for Patients With HCC

Rachna T. Shroff, MD, University of Arizona Cancer Center
October 11th 2022
Video

Rachna T. Shroff, MD, MS, discusses remaining unmet needs for patients with hepatocellular carcinoma.

Richard Kim, MD, professor, Moffitt Cancer Center.

Dr. Kim on the Evolution of Frontline Treatment in HCC

Richard Kim, MD
October 11th 2022
Video

Richard Kim, MD, discusses the evolution of frontline treatment in hepatocellular carcinoma.